Table 1.
Plant host | Vector | Biologic target | Development stage | References |
---|---|---|---|---|
N. benthamiana | Nonviral vector | Influenza A H5N1 HA VLP vaccine | Phase I/II human trial | [38, 39] |
N. benthamiana | TMV | NHL personalized vaccine | Phase I human trial | [37, 40] |
N. benthamiana | CPMV | BTV 4-component VLP vaccine | Preclinical | [30] |
N. benthamiana (WT, ΔXF) | TMV/PVX | Tetravalent antibody WNV therapeutic | Preclinical | [28, 41] |
N. benthamiana | TMV | Cellulases for ethanol production | Early development | [1, 42] |
N. benthamiana | TMV/PVX | Ebola immune complex-based vaccine | Preclinical | [27, 43] |
N. benthamiana | TMV, BeYDV, CPMV | HBcAg nonenveloped VLP vaccine | Preclinical | [19, 44] |
Lettuce, N. benthamiana | TMV/PVX, BeYDV | Ebola therapeutics based on MAb | Preclinical | [18, 32, 34, 45] |
Lettuce, N. benthamiana | TMV, BeYDV | Norovirus NVCP VLP vaccine | Preclinical | [19, 34, 46] |
Lettuce, N. benthamiana | TMV/PVX, BeYDV | WNV therapeutics based on MAb | Preclinical | [17, 28, 34] |
Lettuce, N. benthamiana (WT, ΔXF) | TMV, BeYDV | WNV DIII vaccine | Preclinical | [31, 34, 47] |
HA: hemagglutinin; VLP: virus-like particle; NHL: non-Hodgkin's lymphoma; BTV: bluetongue virus; WT: wild-type; ΔXF: plants with double knockdown of β-1,2-xylose and core α-1,3-fucose; WNV: West Nile virus; HBcAg: hepatitis B core antigen; MAb: monoclonal antibody; NVCP: Norwalk virus capsid protein; DIII: domain III of envelope protein.